Amag endures an FDA rejection; Advaxis teams up with Biocon on cancer drug;

@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech

@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce

@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce

@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce

> The FDA rejected Amag Pharmaceuticals' ($AMAG) effort to widen the label for Feraheme, its drug to treat iron deficiency anemia. More

> Advaxis ($ADXS) has teamed up with India's Biocon to co-develop ADXS-HPV, an immunotherapy for HPV-associated cervical cancer, in India and other emerging markets. News

> EnVivo Pharmaceuticals has kicked off a Phase III trial of EVP-6124, an alpha-7 potentiator designed to treat Alzheimer's disease. Release

Medical Device News

@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev

@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce

@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce

> Diagnostics buoyed Abbott's Q4 numbers, but diabetes sales declined. Report

> Cohera Medical's surgical sealants attracted a $26.3M Series D. More

> St. Jude Medical reports solid growth, predicts more to come. News

Pharma News

@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma

@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton

@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce

@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce

> Now it's New York: Novartis eyes another 500-plus job cuts with plant shutdown. News

> Appeals court gives GSK another shot at AbbVie in HIV drug-pricing fight. Story

> Sanofi's MS pill Aubagio wins final thumbs-up from U.K. cost-effectiveness watchdogs. More

> Par Pharma nabs injectables specialist JHP for $490M in private-equity auction. Report

Drug Delivery News

> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News

> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article

> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story

> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece

> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story

> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item

Diagnostics News

> Researchers from Singapore and China find a new esophageal cancer biomarker. More

> A finger-prick blood test could uncover sports concussions on the field. Article

> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story

> FDA approves Affymetrix's blood test for developmental disabilities. Coverage

> Illumina brings next-generation sequencing to Amgen companion Dx deal. News

> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.